TABLE 3.

Susceptibilities of strains to quinolones and other agents

Strain (plasmid)aGenotypePresence/ absence of reserpinebMIC in μg/ml in (factor change in resistance)c
NORCIPSPARMOXINALCTRH33342EB
ISP7948325 pig-1310.5 (1)0.25 (1)0.125 (1)0.06 (1)200 (1)0.5 (1)2 (1)1 (1)
ISP794+0.5 (1)0.25 (1)0.125 (1)0.06 (1)1 (1)
MT231428325 pig-131 flqB8 (16)2 (8)0.5 (4)0.06 (1)800 (4)8 (16)16 (8)8 (8)
MT23142+2 (4)0.5 (2)0.25 (2)0.06 (1)2 (4)
BF168325 pig-131 arlS::Tn917LTV1210.250.06400222
BF16+0.5 (1)0.25 (1)0.125 (1)0.06 (1)1 (1)
QT18325 pig-131 norR::cat4 (8)2 (8)2 (16)0.5 (8)400 (2)2 (4)2 (1)4 (4)
QT1+1 (2)0.5 (2)0.25 (2)0.125 (2)2 (2)
QT28325 pig-131 norR::cat4 (8)2 (8)2 (16)0.5 (8)400 (2)2 (4)2 (1)4 (4)
QT2+1 (2)0.5 (2)0.25 (2)0.125 (2)2 (2)
KL820RN4220 norA::cat0.33 (.6)0.16 (.6)0.06 (.4)0.06 (1)400 (2)2 (4)2 (1)0.33 (.3)
RN63908325-4 Hla+ Prt+0.50.250.1250.062000.521
RN6911RN6390 agr::tetM0.50.250.1250.062000.521
ALC136RN6390 sar::Tn917LTV10.50.250.1250.062000.521
ALC135RN6390 agr::tetM sar::Tn917LTV10.50.250.1250.062000.521
MT12228325 pig-131 grlA flqB gyrA25664881000321616
MT1222+6432444
ISP794(pQT4)2 (4)0.5 (2)0.125 (1)0.06 (1)200 (1)2 (4)3 (1.5)4 (4)
MT23142(pQT4)820.50.068008648
BF16(pQT4)210.250.06400242
QT1(pQT4)2 (4)0.25 (1)0.125 (1)0.06 (1)200 (1)2 (4)2 (1)4 (4)
QT2(pQT4)20.250.1250.06200224
KL820(pQT4)0.50.250.060.06400220.5
RN6390(pQT4)10.50.1250.062000.522
RN6911(pQT4)0.50.250.1250.062000.521
ALC136(pQT4)0.50.250.1250.062000.521
ALC135(pQT4)0.50.250.1250.062000.521
MT1222(pQT4)25664881,000321616
  • a Strains harboring plasmid pQT4 were grown in the presence of erythromycin (5 μg/ml).

  • b −, reserpine absent; +, reserpine present.

  • c NOR, norfloxacin; CIP, ciprofloxacin; SPAR, sparfloxacin; MOXI, moxifloxacin; NAL, nalidixic acid; CTR, cetrimide; EB, ethidium bromide; H3342, Hoechst 33342.